EGCG in Oncology Overview

What EGCG is, how it relates to green tea, and why it is studied in oncology

EGCG stands for epigallocatechin-3-gallate. It is the most abundant and most studied catechin found in green tea (Camellia sinensis). Many readers know green tea, but not the name EGCG. Throughout this topic, when you see EGCG in research papers, think the main anticancer catechin in green tea.

At a Glance

• What it is: A green tea catechin and polyphenol

• Why it matters: It targets multiple cancer hallmarks at once, including growth-factor signalling, apoptosis, angiogenesis, and metastasis

• Best-supported use today: Adjunctive and chemopreventive use

• Strongest evidence: Large preclinical literature with meaningful epidemiological and early clinical support

• Main limitation: Oral bioavailability is poor, especially for systemic exposure

What is EGCG?

EGCG is the dominant catechin in green tea and usually accounts for most of the biological interest in oncology studies of green tea extracts. Green tea also contains other catechins such as EGC, ECG, and EC, but EGCG is the best-studied component.

Why the green tea connection matters

People often know the food or beverage, not the research compound. In practical terms, EGCG is the part of green tea that receives the most detailed anticancer attention in laboratory, epidemiological, and supplement research.

Why is EGCG studied in oncology?

EGCG has attracted interest because it can influence multiple pathways at once.

Research suggests EGCG may:

• inhibit EGFR, MAPK, PI3K/Akt, and mTOR signalling

• promote apoptosis

• suppress angiogenesis and metastasis-related pathways

• modulate inflammation, NF-κB, and STAT3

• influence immune behaviour in the tumour microenvironment

• support chemoprevention and recurrence-reduction strategies in selected contexts

Clinical Positioning

Current evidence best supports EGCG as an investigational adjunct and chemopreventive compound rather than a standalone treatment.

Its most credible current uses are in the overlap between:

• long-term prevention-oriented strategies

• supportive integrative oncology use

• pathway-focused adjunctive care

• selected epidemiology-backed cancer contexts such as prostate, colorectal, breast, and upper GI relevance

Evidence Quality Rating

4/5 — Strong preclinical and early clinical evidence

This rating reflects a very large mechanistic literature, substantial epidemiological support, and multiple early human trials. It remains limited by poor bioavailability and fewer large late-stage interventional oncology trials.

Where to Go Next

• Evidence Summary

• Anticancer Mechanisms

• Evidence by Cancer Type

• Immune Effects

• Pharmacokinetics & Metabolism

• Dosing & Timing

• Safety & Interactions

• Sourcing Quality EGCG

Key References

Anticancer Molecular Mechanisms of Epigallocatechin-3-Gallate (EGCG) https://onlinelibrary.wiley.com/doi/full/10.1002/fsn3.70735

Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications https://pmc.ncbi.nlm.nih.gov/articles/PMC10343677/

The roles of epigallocatechin gallate in the tumour microenvironment, metabolic reprogramming, and anti-cancer therapy https://www.frontiersin.org/articles/10.3389/fimmu.2024.1331641/full

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.

© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.